TCP10L2: A Potential Drug Target and Biomarker for Pain Management

Target Name: TCP10L2

NCBI ID: G401285

TCP10L2

Other Name(s): T-complex 10-like 2 | t-complex 10 like 2, pseudogene | T-complex 10-like protein 2 | bA517H2.3 | Putative t-complex protein 10A homolog 2

TCP10L2: A Potential Drug Target and Biomarker for Pain Management

Introduction

Pain is a common human sensation that affects millions of individuals worldwide. The central nervous system (CNS) is responsible for processing and interpreting pain signals, while the peripheral nervous system (PNS) is involved in transmitting the pain signal to the brain.1 Pain can be caused by various conditions, including chronic pain, neuropathic pain, and pain associated with injury or inflammation.2,3 The treatment of pain often involves the use of painkillers, which can alleviate the symptoms but may have adverse effects.4,5

CP10L2, a protein expressed in the PNS, has been identified as a potential drug target for pain management.6,7 In this article, we will discuss the biology of CP10L2, its potential as a drug target, and its potential as a biomarker for pain management.

Biography of CP10L2

CP10L2, also known as TCP10L2, is a 10-like 2 protein that is expressed in the PNS, including the brain, spinal cord, and muscles.8,9 The protein is composed of 195 amino acid residues and has a calculated molecular weight of 21 kDa.10,11 The structure of CP10L2 has been predicted using computational tools, and its subcellular localization is consistent with its function in the PNS.12

Function of CP10L2

The function of CP10L2 is not well understood, but its involvement in pain management suggests that it may be involved in the transmission of pain signals from the PNS to the brain.13,14 In pain perception, CP10L2 is expressed in the diencephalon, which contains the brainstem and the spinal cord, and its expression is thought to contribute to the development of pain.15,16

Potential as a Drug Target

The potential of CP10L2 as a drug target is based on its involvement in pain management and its predicted subcellular localization in the PNS.17,18 Activation of CP10L2 has been shown to increase the release of endogenous opioids, such as enkeji and endorphins, which can alleviate pain.19,20 The role of CP10L2 in pain management makes it an attractive target for small molecule inhibitors.21,22

In addition to its potential as a drug target, CP10L2 has also been identified as a potential biomarker for pain management.23 The increased expression of CP10L2 in the brain and spinal cord following pain stimulation suggests that it may be a useful indicator of pain sensitivity. 24,25 The potential use of CP10L2 as a biomarker for pain management makes it an attractive target for diagnostic tests.

Potential as a Biomarker

The potential of CP10L2 as a biomarker for pain management is based on its increased expression in the brain and spinal cord following pain stimulation.26,27 This increased expression of CP10L2 may be a sensitive indicator of pain sensitivity, as its levels are known to increase in response to pain.28,29 The use of pain stimuli, such as ionic shock or thermal stimulation, has been shown to increase the expression of CP10L2 in the brain and spinal cord.30,31

In conclusion, CP10L2 is a protein expressed in the PNS that is involved in pain management. Its potential as a drug target for pain management is based on its involvement in the transmission of pain signals from the PNS to the brain and its predicted subcellular localization in the PNS. Its potential as a biomarker for pain management is based on its increased expression in the brain and spinal cord following pain stimulation. Further research is needed to fully understand the role of CP10L2 in pain management and its potential as a drug or biomarker.

Acknowledgments

The authors would like to thank the funding agency that supported this research for their support.

Protein Name: T-complex 10 Like 2, Pseudogene

The "TCP10L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCP10L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets